The latest meeting of the European Medicines Agency’s Committee for Medicinal Products for Human Use has seen Accord Healthcare win positive opinions for its two denosumab biosimilars, at the same time as Celltrion has gained an endorsement for a second ustekinumab biosimilar.
While CHMP positive opinions do not constitute formal approval, they are typically converted into pan-European marketing authorizations by the European...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?